Your browser doesn't support javascript.
loading
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population.
De Laurentiis, Michelino; Borstnar, Simona; Campone, Mario; Warner, Ellen; Bofill, Javier Salvador; Jacot, William; Dent, Susan; Martin, Miguel; Ring, Alistair; Cottu, Paul; Lu, Janice; Ciruelos, Eva; Azim, Hamdy A; Chatterjee, Sanjoy; Zhou, Katie; Wu, Jiwen; Menon-Singh, Lakshmi; Zamagni, Claudio.
Afiliação
  • De Laurentiis M; Division of Breast Medical Oncology, Department of Breast and Thoracic Oncology Director, Istituto Nazionale Tumori IRCCS "Fondazione Pascale", Napoli, Italy. m.delaurentiis@istitutotumori.na.it.
  • Borstnar S; Institute of Oncology Ljubljana, Ljubljana, Slovenia.
  • Campone M; Western Cancer Institute, Nantes, France.
  • Warner E; Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Bofill JS; Virgen del Rocío University Hospital, Biomedicine Institute, Seville, Spain.
  • Jacot W; Montpellier Cancer Institute, Montpellier, France.
  • Dent S; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.
  • Martin M; Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
  • Ring A; Gregorio Marañón General University Hospital, GEICAM, Universidad Complutense, CIBERONC, Madrid, Spain.
  • Cottu P; Royal Marsden Hospital NHS Foundation Trust, Sutton, UK.
  • Lu J; Curie Institute, Paris, France.
  • Ciruelos E; USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
  • Azim HA; University Hospital 12 de Octubre, Clara Campal Comprehensive Cancer Center (HM CIOCC), Madrid, Spain.
  • Chatterjee S; Faculty of Medicine, Cairo University, Cairo, Egypt.
  • Zhou K; Tata Medical Center, Kolkata, India.
  • Wu J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Menon-Singh L; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Zamagni C; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Breast Cancer Res Treat ; 191(1): 223-224, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34625861
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article